Castle Biosciences Inc (CSTL)

Apr 3, 2025, 7:00 AM EDT - 1 day ago

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test

Apr 1, 2025, 4:30 PM EDT - 2 days ago

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Mar 28, 2025, 4:15 PM EDT - 6 days ago

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

Mar 7, 2025, 7:00 AM EST - 4 weeks ago

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Feb 27, 2025, 10:09 PM EST - 5 weeks ago

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 5 weeks ago

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

Feb 25, 2025, 4:30 PM EST - 5 weeks ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Feb 12, 2025, 4:30 PM EST - 7 weeks ago

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

Feb 6, 2025, 7:00 AM EST - 2 months ago

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Jan 17, 2025, 7:00 AM EST - 2 months ago

Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

Jan 12, 2025, 6:00 PM EST - 2 months ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

Jan 6, 2025, 7:00 AM EST - 3 months ago

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test

Dec 23, 2024, 7:00 AM EST - 3 months ago

Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

Dec 19, 2024, 7:00 AM EST - 3 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2024, 7:00 AM EST - 4 months ago

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Nov 20, 2024, 7:00 AM EST - 4 months ago

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 7:00 AM EST - 4 months ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

Nov 8, 2024, 7:00 AM EST - 5 months ago

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

Nov 7, 2024, 7:00 AM EST - 5 months ago

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett's Esophagus Test

Nov 6, 2024, 7:00 AM EST - 5 months ago

Use of Castle Biosciences' DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024

Nov 4, 2024, 7:33 PM EST - 5 months ago

Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 5 months ago

Castle Biosciences Reports Third Quarter 2024 Results

Oct 29, 2024, 4:30 PM EDT - 5 months ago

Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients

Oct 20, 2024, 5:00 AM EDT - 5 months ago

Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors

Oct 16, 2024, 7:00 AM EDT - 6 months ago

Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential

Oct 14, 2024, 7:00 AM EDT - 6 months ago

Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024

Oct 11, 2024, 7:00 AM EDT - 6 months ago

Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin

Oct 9, 2024, 7:00 AM EDT - 6 months ago

New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences' DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions

Oct 2, 2024, 7:00 AM EDT - 6 months ago

Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas

Sep 27, 2024, 5:15 PM EDT - 6 months ago

New Data at ASTRO 2024 Shows Castle Biosciences' DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Sep 23, 2024, 7:00 AM EDT - 6 months ago

New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences' TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett's Esophagus

Sep 16, 2024, 7:00 AM EDT - 7 months ago

Castle Biosciences' Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year

Sep 11, 2024, 7:00 AM EDT - 7 months ago

DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms

Sep 5, 2024, 7:00 AM EDT - 7 months ago

Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

Aug 16, 2024, 6:41 AM EDT - 8 months ago

Castle Biosciences: Inflection Into Profitability

Aug 5, 2024, 10:35 PM EDT - 8 months ago

Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:05 PM EDT - 8 months ago

Castle Biosciences Reports Second Quarter 2024 Results

Jul 30, 2024, 7:00 AM EDT - 8 months ago

Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

Jul 22, 2024, 7:00 AM EDT - 9 months ago

Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma

Jul 15, 2024, 7:00 AM EDT - 9 months ago

Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024

Jul 11, 2024, 7:00 AM EDT - 9 months ago

Castle Biosciences Honored with Top Workplaces Awards

Jul 8, 2024, 8:40 AM EDT - 9 months ago

Top 5 Health Care Stocks That May Explode In July

NRC OMI PCRX SAVA

Jun 24, 2024, 7:00 AM EDT - 10 months ago

Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher® Test

Jun 14, 2024, 4:30 PM EDT - 10 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner

May 30, 2024, 4:30 PM EDT - 11 months ago

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

May 29, 2024, 4:30 PM EDT - 11 months ago

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

May 15, 2024, 7:00 AM EDT - 11 months ago

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

May 14, 2024, 7:00 AM EDT - 11 months ago

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

May 10, 2024, 7:00 AM EDT - 11 months ago

Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”

May 8, 2024, 4:30 PM EDT - 11 months ago

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result